Re­gen­eron, Sanofi are ready to de­but the 6th PD-1/L1. Is it still pos­si­ble to stand out from the grow­ing crowd?

8 years ago
R&D

When can FDA 'refuse to file' NDAs and BLAs? New draft guid­ance ex­plains

8 years ago
Pharma

SEC charges Provec­tus found­ing CEO Dees with loot­ing mil­lions for girl­friends’ cos­met­ic surg­eries, trav­el and more

8 years ago
People

Medi­gene, RXi strike re­search deal to im­prove TCRs; Bris­tol-My­ers pays PsiOxus $15M mile­stone for tri­al-ready ...

8 years ago
News Briefing

Ex-Dez­i­ma CEO co-founds NASH start­up, fly­ing in­to Phase IIB with €25 mil­lion

8 years ago
Startups

Sanofi's R&D day pos­es some big chal­lenges as skep­tics cir­cle in wake of a Deng­vax­ia fi­as­co

8 years ago
Bioregnum
Opinion

Aduro buries an­oth­er can­cer vac­cine af­ter CRS-207 joins the line­up of clin­i­cal dis­as­ters

8 years ago
R&D

#ASH17: Ab­b­Vie, Roche boast stel­lar PhI­II leukemia da­ta for a “break­through” com­bo with block­buster am­bi­tions

8 years ago
R&D

Al­ler­gan buys an ail­ing Re­pros, bag­ging a women’s health drug for the pipeline

8 years ago
Deals
Pharma

GSK of­fers en­cour­ag­ing da­ta on BC­MA-tar­get­ing armed an­ti­body, set­ting stage for a re­turn to late-stage can­cer stud­ies

8 years ago
R&D

In lat­est blow to Eli Lil­ly, Sanofi wins FDA OK for Hu­ma­log me-too

8 years ago
Pharma

Hookipa rais­es $60M to fund im­munother­a­py R&D; Roche bags Io­n­is op­tion for $45M; Re­gen­eron fights back against ...

8 years ago
News Briefing

#ASH17: Spark trig­gers a back­lash as ear­ly he­mo­phil­ia A gene ther­a­py da­ta looks shaky

8 years ago
R&D
Cell/Gene Tx

#ASH17: Sy­ros evis­cer­at­ed by in­vestor back­lash as lead drug flails bad­ly in PhII

8 years ago
R&D

Can GSK’s new R&D strat­e­gy re­sus­ci­tate the worst per­former in Big Phar­ma?

8 years ago
Bioregnum
R&D

#ASH17: Ve­rastem's Ab­b­Vie castoff is head­ed for the FDA — even af­ter miss­ing over­all sur­vival goal

8 years ago
R&D

#ASH17: Blue­print el­bows its way to cen­ter ring with ear­ly da­ta and a plan to seek quick FDA OK

8 years ago
R&D

#ASH17: How does No­var­tis’ Kym­ri­ah DL­B­CL da­ta stack up head­ing straight to a CAR-T show­down with Gilead?

8 years ago
R&D

#ASH17: The BC­MA-tar­get­ed CAR-T bb2121 from blue­bird and Cel­gene takes a star turn in the spot­light

8 years ago
R&D

#ASH17: Roche un­veils stel­lar PhII DL­B­CL da­ta for one of its top hema­tol­ogy drugs in the pipeline

8 years ago
R&D

#ASH17: Seat­tle Ge­net­ics CEO Clay Sie­gall has an an­swer for the skep­tics doubt­ing Ad­cetris da­ta for Hodgkin lym­phoma

8 years ago
R&D

Ery­tech shares crater as PhI­Ib AML study flops; Syn­log­ic, Gingko col­lab­o­rate on dis­cov­ery work; Ac­tive Biotech forced ...

8 years ago
News Briefing

M&A slows to a trick­le in 2017, but Big Phar­ma could be on deck for mega deals

8 years ago
Deals

Ac­tivists threat­en to push for a sale of Alex­ion if ex­ecs can't jack up stock price

8 years ago
Pharma
First page Previous page 1074107510761077107810791080 Next page Last page
A service from the Financial Times